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Several recent studies have further clarified the role of chemotherapy innewly diagnosed ana-
plastic glioma. For newly diagnosed glioblastoma, combined daily radiotherapy with daily
temozolomide followed by six cycles of adjuvant temozolomide improves overall survival.
This benefit is especially observed in patients with a methylated promotor of theMGMT gene
which encodes an alkyltransferase; this observation however, needs confirmation. Although
oligodendroglial tumours are sensitive to chemotherapy, classical adjuvant nitrosourea-based
chemotherapy does not improve overall survival in newly diagnosed anaplastic oligodendro-
glioma, even in the subset of 1p/19q loss tumours. It may increase progression-free survival
however, and further studies must show if combined modality treatment with daily chemo-
therapy during radiotherapy increases survival. Trials exploring the role of chemotherapy in
low-grade glioma are ongoing. No standard chemotherapy is currently available for highly
anaplastic glioma failing first-line temozolomide-based therapy.
 2005 Elsevier Ltd. All rights reserved.1. Introduction
Randomized trials on malignant glioma conducted from 1970
to the 1990s clearly established the role of radiotherapy in the
treatment of anaplastic glioma, but all failed to demonstrate a
significant increase in survival by the addition of chemother-
apy (Table 1).1,2 It took a large individual patient data based
meta-analysis comprising over 3000 patients to show that
adjuvant chemotherapy may improve the 2-year survival by
only 5%, from 15% to 20%.3 In recent years, the role of chemo-
therapy in glioma has been met with renewed interest mainly
due to two developments: the recognition of the sensitivity to
chemotherapy of 1p/19q loss oligodendrogliomas; and theer Ltd. All rights reserved
fax: +31 10 4391031.
c.nl (M.J. van den Bent)availability of temozolomide, a novel alkylating agent with
good penetration in the central nervous system. In the
1990s a series of phase II trials have shown activity of tem-
ozolomide (TMZ) against recurrent glioblastoma and anaplas-
tic astrocytoma. After approval in 1999, TMZ has largely
replaced nitrosoureas in the treatment of glioma, although a
formal comparative trial was never conducted. Recently, a
randomized trial has demonstrated a superior survival in
newly diagnosed glioblastoma multiforme (GBM) patients,
treated with TMZ and radiation.4 Both PCV combination che-
motherapy (procarbazine, CCNU and vincristine) and tem-
ozolomide were investigated as treatment for recurrent and
newly diagnosed anaplastic oligodendrogliomas. This review.
.
Table 1 – Median, 1- and 2-year survival after various postoperative adjuvant treatment in high-grade glioma, in bold the
outcome of EORTC study 26981
Reference Treatment Median survival 1-year survival (%) 2-year survival (%)
Walker 19781 Supportive care 3 mo 3 0
BCNU 4 mo 12 0
RT 8 mo 24 1
RT + BCNU 8 mo 32 5
Glioma Meta-analysis Trialists Group3 RT 40 15
RT + CTX 46 20
EORTC 269814 RT 12 51 10
RT + temozolomide 15 61 27
RT, radiotherapy; CTX, chemotherapy; SRS, stereotactic radiosurgery; BCNU, carmustine; mo, months.
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to highlight some novel developments and directions for fu-
ture research.
2. Temozolomide: pharmacology and
mechanisms of action
TMZ is an oral alkylating agent, which is rapidly (peak con-
centrations after 30–90 min) absorbed, penetrates into all
body tissues including the central-nervous system and spon-
taneously converts into the active metabolite MTIC.5
Although recommended to be taken in fasting state, food will
have little influence with a 10% reduced AUC and a delayed
peak concentration.6 Similar to nitrosoureas, TMZ acts as a
DNA alkylating agent. Alkylation of the O6-position of guan-
ine is one among many DNA adducts formed, but it is of ma-
jor importance for the induction of mutations and the
cytotoxic action of these drugs. During subsequent DNA rep-
lication, the methylated guanine could be shown to be paired
with thymidine instead of cytidine, which initiates futile mis-
match repair and eventually may induce apoptosis. Cells have
the capacity of restoring guanine through the DNA excision
repair enzyme O6-methylguanine–DNA methyltransferase
(MGMT), also known as O6-alkyl-guanine–alkyltransferase
(AGAT) (reviewed by Gerson7). During this saturable process
the enzyme is consumed. High endogenous MGMT activity
in cancer cells blunts the treatment-effect of alkylating agent
chemotherapies creating a resistant phenotype and may be
an important determinant of treatment failure.8–12 Silencing
the MGMT gene by promoter methylation that impairs
expression of the DNA repair enzyme has been associated
with prolonged survival in glioma patients treated with nitro-
soureas or with TMZ.13,14
3. Temozolomide in recurrent glioma
TMZ has demonstrated its activity initially in patients with
recurrent high-grade glioma. Three pivotal phase II studies
with identical entry criteria were conducted for patients with
GBM and with anaplastic astrocytoma (AA). Despite disap-
pointingly low objective response rates in GBM of 5% and
7%, respectively, but with an interesting response rate of
35% in the AA trial, these studies suggested an increase in
the fraction of patients being progression-free at 6 monthscompared to a historical database.15–17 Subgroup analysis
suggested that mainly patients who had not received prior
adjuvant chemotherapy benefited from this treatment.
4. Temozolomide schedules
In vitro and phase I studies have established the initial stan-
dard dosing of TMZ (150–200 mg/m2/day) for 5 days every 4
weeks. Novel continuous administration schedules have
since been developed, allowing for more intensive and dose-
dense regimens. Using these low-dose but daily schedules,
the actual dose-intensities could be increased up to over 2-
fold (e.g., oneweek on/oneweek off, three weeks on/oneweek
off, 42 days every 60 days).18–20 The protracted administration
of temozolomide, even at relatively low daily doses, was
shown to lead to significant and prolonged depletion of
MGMT activity.21 Although this may potentially enhance the
antitumour activity of the agent, to date there are no conclu-
sive data available demonstrating that these more dose-dense
regimens offer clinically relevant increased anti tumour activ-
ity.22,23 No randomized studies exist, and the reported im-
proved outcome in terms of 6 months progression-free
survival may be a matter of patient selection. One novel ad-
verse effect of the continuous temozolomide administration
schedules is induction of profound lymphocytopenia with
low CD4 counts.24 The common use of corticosteroids in brain
tumour patients adds further to an immunodeficient state,
predisposing patients to opportunistic infections. Increased
incidence of opportunistic infections, in particular pneumo-
cystis carinii pneumonia and Kaposi sarcoma, has been re-
ported.25,26 Monitoring of CD4 counts and antibiotic
prophylaxis with trimethroprim/sulfametoxazole or pentam-
idine inhalations for patients at risk have been proposed.
5. Temozolomide for patients with
newly diagnosed glioblastoma
Based on the activity in recurrent glioma and in vitro data sug-
gesting additive or supra-additive activity when TMZ was
administered concomitantly with radiotherapy, a phase II trial
investigated the administration of low-dose TMZ daily (75 mg/
m2 daily 7/7 days week) with concomitant radiotherapy for up
to 7 weeks, followed by six cycles of adjuvant TMZ (5-days
q28 days). This treatment was shown to be feasible and well
584 E U R O P E A N J O U R N A L O F C A N C E R 4 2 ( 2 0 0 6 ) 5 8 2 –5 8 8tolerated.26 The European Organisation for Research and
Treatment of Cancer (EORTC) and the National Cancer Insti-
tute of Canada (NCIC) Clinical Trials Group compared this
new combined modality regimen to standard radiotherapy
alone in a large prospective randomized phase III trial on 573
patients.4 Primary trial endpoint was survival. This study
unequivocally demonstrated that the combination of TMZ
and radiotherapy (RT) followed by up to six cycles of adjuvant
TMZ improves survival. With combined modality treatment,
the 2-year survival increased from 10% to 26% (Table 1). Sub-
group analyses suggested that patients of all age groups (up
to age 70 allowed in the trial) and independent of prior tumour
resection benefited from this treatment. As in other fields of
oncology, patients with a modest performance status did not
benefit from the addition of chemotherapy. Overall, the com-
bined treatment was well tolerated, and the main reason for
early discontinuation was disease progression.
The clinical relevance of the mechanistic implication of
the DNA repair enzyme MGMT in alkylating chemotherapy
was tested in this randomized EORTC/NCIC trial. Samples
from 206 patients could be analysed for the status of the
MGMT gene promoter using methylation-specific PCR
(MSP).27 In 45% of tumour samples, the MGMT gene promoter
was methylated, and the gene was silenced. Overall, patients
with a silenced MGMT gene had longer survival. Break down
of the data by treatment strongly suggests that the MGMT
methylation status is a predictive marker for benefit from
TMZ chemotherapy. For patients in the TMZ/RT arm, the 2-
year survival rate was 46% when their tumour presented a
methylated MGMT status in contrast to only 14% in patients
with an unmethylated MGMT gene promoter (Table 2). Thus,
in this molecularly defined subgroup the TMZ is even more
effective increasing the median survival by 9 months to
21.7, while patients with an unmethylated MGMT gene pro-
moter had little, if any, TMZ-derived benefit with a median
survival of 12.7 months.
Confirmation of these results in a second trial would then
suggest that only patients whose tumours comprise a methyl-
atedMGMT promoter (thus silenced gene) should receive TMZ,
while for other patients, alternative strategies must be consid-
ered. Strategies aiming at overcoming MGMT-mediated resis-
tance are currently developed. Administration of agents like
O6-benzyl-guanine, a non-cytotoxic substrate of MGMT, or in
combinationwith nitrosoureas is limited by increased systemic
toxicity, mainly myelosuppression. Continuous administration
of temozolomidehasbeenshowntodeplete intracellularMGMT
and novel dose-dense schedules are currently explored as adju-
vant treatment in large randomized trials.Table 2 – Median survival and 2-year survival in EORTC study
promoter27
Treatment Median survival (mo
Radiotherapya Rad
plus te
Unmethylated MGMT promotor 11.8
Methylated MGMT promotor 15.3
a 72% of the patients in the radiotherapy-arm received alkylating chemCurrent phase II and phase III studies are investigating
whether the addition of agents targeting the EGF receptor path-
way (e.g., the tyrosin kinase inhibitor erlotinib), VEGF and PDGF
receptors (e.g., PTK787) or the tumour vasculature (e.g., the alp-
haVbeta3 inhibitor cilengitide) to the combination of TMZ and
radiotherapy further improve survival in newly diagnosedGBM.
6. Temozolomide in elderly
The first randomized studies on anaplastic gliomahave clearly
shown the superiority of radiotherapy over chemotherapy.1
However, in elderly patients with a particularly dismal prog-
nosis, simple and least toxic therapies are required. Encour-
aged by reports of high response and disease stabilization
rates with TMZ chemotherapy in previously untreated GBM
patients,28 chemotherapy in lieu of radiotherapy has been
evaluated in a limited number of patients in uncontrolled tri-
als.29 Chinot and colleagues reported a median survival of 6.4
month in a prospective study on 32 patients.29 Glantz and col-
leagues observed in a non-randomized study a survival out-
come after treatment with temozolomide (n = 32) that was at
least as good as ‘historical controls’ treated with radiotherapy
in the same time period within the same institution.30 Fur-
thermore, both groups were comparable with respect to
known prognostic factors. The treatment outcome of these
two studies appears similar compared to the results of radio-
therapy only in elderly or poor prognosis GBM patients.31,32
In both studies toxicity was modest, although in one study
dose delays and dose reductions were needed in 38% and
13% of patients. This underlines that a more cautious ap-
proach to chemotherapy is needed in elderly patients. Both
studies give support for further investigations into this ap-
proach. The NCIC together with the EORTC are currently plan-
ning a randomized trial comparing standard hypofractionated
radiotherapy with TMZ added to the same RT, or TMZ alone.
7. Temozolomide in combination with
other cytotoxic agents
In the past years results, of several novel combinations of
alkylating agents with drugs with a different mode of action
investigated in recurrent GBM have been published: cisplatin
and TMZ,33 marimastat and TMZ,34 cisretinoic acid and
TMZ,35 thalidomide and carmustine36 (Table 3). Each of these
combinations report high response rates and favourable per-
centages of patients free from progression at six months.
Invariably, the authors conclude the results are promising,
and then move on to the next combination. In the absence26981 in relation to the methylation status of the MGMT








Table 3 – A summary of recent studies on recurrent glioblastioma multiforme, except for *, recurrent anaplastic
astrocytoma
Drugs n CR + PR (%) 6 mo PFS (%)
Yung et al.16 TMZ 150–200 mg/m2 day 1–5 every 4 weeks 112 5.4 21
Procarbazine 113 5.3 8
Yung15* TMZ 150–200 mg/m2 day 1–5 every 4 weeks 162 35 46
Jaeckle35 TMZ 150–200 mg/m2 day 1–5 every 4 weeks + cis retinoic acid 40 4.5 32
Groves34 TMZ 150–200 mg/m2 day 1–5 every 4 weeks + marimastat 44 13.6 39
Fine36 BCNU 200 mg/m2 + 800–1200 mg thalidomide every 6 weeks 40 24 27
Brandes33 TMZ 200 mg/m2 day 1–5 + cisplatin 75 mg/m2 every 4 weeks 50 20 34
Wick23 TMZ 150 mg/m2 one week on/one week off 21 10 43
Khan22 TMZ 75 mg/m2 daily for 6 weeks in 10 week cycles 28 0 19
Prados41 BCNU 150 mg/m2 + TMZ single dose 550 mg/m2 36 5.5 21
Brandes61 BCNU 80 mg/m2 day 1–3 40 15 17.5
Brandes62 BCNU 100 mg/m2 day 1 + 175 mg/m2 CPT-11
weekly for 4 weeks in cycles of 6 weeks
42 21.4 30
Kappele63 PCV 63 11 29
Abbreviations: n, number of patients; CR, complete response; PR, partial response; PFS, progression-free survival; BCNU, curmustine; TMZ,
temozolomide; PCV, procarbazine, CCNU and vincristine.
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studies and results may solely reflect patient selection.
Because of the role of MGMT in the resistance to alkylating
chemotherapy, several studies added a MGMT depleting agent
in order to increase efficacy. For this purpose, both drugs with
intrinsic cytotoxic activity as well as drugs that only deplete
MGMT (O6-benzylguanine; O6-BG) were used. As one might
expect, such combinations also increased toxicity and neces-
sitated the use of reduced dosages as compared to the same
agents when given as single agent treatment.37,38 First results
of this strategy showed that adding O6-BG to carmustine did
not induce regression in carmustine resistant gliomas,
although a similar trial in temozolomide pretreated patients
showed some evidence of benefit by adding O6-BG to
TMZ.39,40 A trial exploring the combination BCNU and tem-
ozolomide concluded however that the outcome of the com-
bination appeared of similar efficacy as single agent
temozolomide (Table 3).41
8. Irinotecan
Since its initial report of activity (of irinotecan CPT11) in
recurrent malignant glioma (17% objective response rate in
GBM), this drug was further explored in several single agent
studies.42–44 These did not confirm the high response rates
initially reported. Currently combinational regimens are
being investigated, in particular of temozolomide and irino-
tecan. A study investigating the combination, BCNU and iri-
notecan, yielded a response rate similar to other
combination studies with temozolomide. As irinotecan is
mainly metabolized in the liver, dependent on the P450 sys-
tem, it can only be reliably administered to patients not using
hepatic enzyme inducing antieptileptic drugs (EIAED).
9. Oligodendroglioma
Oligodendroglioma and to a lesser extent, oligoastrocytoma,
are responsive to chemotherapy. Two-thirds of patients with
recurrent tumours were shown to respond to PCV chemother-apy, consisting of procarbazine, CCNU and vincristine.45,46
The recent finding of a high percentage of these tumours with
a methylated MGMT status (>80%) may in part explain this
clinical feature.47 Further molecular studies showed that in
particular, patients with oligodendrogliomas with loss of het-
erozygosity on both, the short arm of chromosome 1 (1p) and
the long arm of chromosome 19 (19q), are very sensitive to
PCV chemotherapy: almost all patients responded to PCV che-
motherapy.48,49 The EORTC conducted two phase II trials eval-
uating single agent standard schedule TMZ as first and
second-line therapy in patients with recurrent or progressive
anaplastic oligodendroglioma and oligoastrocytoma.50,51 High
response rates of 53% (26% complete responses) and 25%were
observed to first and second-line temozolomide chemother-
apy, respectively. Genetic analysis confirmed the importance
of 1p/19q loss for chemotherapy response also for TMZ.52
The currently available data suggest that about 55–65% of pa-
tients with recurrent oligodendroglioma respond to first-line
chemotherapy, but in second-line the response rate dropped
to 20–25% regardless of the chosen sequence of treatment:
temozolomide first or PCV first.
Both the RTOG and the EORTC investigated the addition of
PCV chemotherapy to radiotherapy in newly diagnosed ana-
plastic oligodendroglioma.53 The RTOG study used neo-
adjuvant with a dose intensified PCV schedule, whereas the
EORTC study used classical adjuvant design with standard
PCV; in both studies the control arm received radiotherapy
only (but further treatment at the time of progression was left
to the discretion of the treating physician). Most patients re-
ceived further chemotherapy at the time of progression.
Although both studies observed an increase in progression-
free survival in the PCVarm, this did not translate in to an in-
crease in overall survival. Patients with 1p/19q loss had a
clearly better outcome (median survival over 6–7 years as
compared to 2–3 years in patients without 1p/19q loss), but
the improved outcome was regardless of treatment. Both
studies showed, that in this chemosensitive tumour, the tim-
ing of chemotherapy was not relevant (at first diagnosis or at
recurrence), as long as it was given.
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ies on adjuvant treatment in glioma is that the EORTC study,
on concurrent and adjuvant temozolomide in chemoresis-
tant GBM, resulted in survival benefit, whereas a similar
EORTC and RTOG trials on chemosensitive oligodendrogli-
oma failed to provide survival benefit. Perhaps the most sig-
nificant difference between these trials is the combination of
radiotherapy with daily temozolomide in the GBM study. It
may well be that this part of the treatment is the essential
part for the improved outcome, but this must be proven in
new trials.
Despite the absence of a formal trial many clinicians to-
day propose upfront temozolomide TMZ as first treatment
in 1p/19q loss oligodendroglioma. This is clearly an experi-
mental approach, based on the assumption that RT is likely
to induce delayed cognitive deficits. This assumption is ques-
tionable though if modern RT techniques are used with dose
fractions of less than 2 Gy.54 Eventually, this may be more a
matter of side-effects, and one should realize that especially
for limited size lesions, RT offers an effective treatment of
short duration (6 weeks instead of 12–24 months of
chemotherapy).
10. Low-grade glioma
Several recently published studies have explored upfront
treatment of newly diagnosed low-grade glioma (in particular
oligodendroglioma) with chemotherapy with either PCV or
temozolomide.55–58 These trials show that objective re-
sponses are rare, despite prolonged disease stabilization in
the majority of patients. Measuring response in low-grade tu-
mours in the absence of contrast enhancement may be par-
ticularly difficult. On MRI abnormalities on T2 weighted
images are unlikely to decrease significantly, and functional
imaging by positron-emission tomography using amino-acid
tracers is not widely available.56 For clinical trials, time to pro-
gression may be the preferred endpoint.59,60
Whether there is truly an advantage in treating these pa-
tients with upfront chemotherapy compared to initial RT is
currently the subject of a randomized EORTC/NCIC phase III
trial. Outside trials, it is questionable whether upfront chemo-
therapy should be given to low-grade glioma (LGG) patients,
even in case of oligodendroglioma with 1p/19q LOH. Radio-
therapy is also a very effective and proven treatment, and in
the end, the choice of therapy may well be a matter of acute
and long-term toxicity based on individual patient factors
and tumour size and location. Whether a short course of
radiotherapy (typically 6 weeks) should be replaced by pro-
longed (proposed duration 1 year) and costly administration
of chemotherapy needs to be proven. Possibly the sequence
of treatment modalities is of lesser or no importance in over-
all survival. Although the addition of TMZ to radiotherapy has
been proven superior in the treatment of aggressive glioblas-
toma, extending this approach to low-grade glioma is poten-
tially harmful. In a disease with median survival rates of 5–7
years, with a significant proportion of patients living 10–15
years or longer, late toxicity of any treatment is a concern.
Here the sequential and prudent use of the treatment modal-
ities may be more optimal than the maximum use of all ther-
apeutic arms upfront.11. Conclusions and outlook
Temozolomide has become themainstay of chemotherapeutic
treatment of high-grade glioma. The use of a cytotoxic agent
with the capacity of crossing the blood–brain barrier in combi-
nation with radiotherapy has a clear impact on progression
and survival of glioblastoma patients. Molecular studies have
shown that specific tumour characteristics like a silenced
MGMT gene may allow tailoring treatment for individual pa-
tients. New trials are planned to confirm these findings, but
also to develop strategies allowing depletion of MGMT in
unmethylated tumours, e.g., by using more intensive treat-
ment schedules, but also to evaluate the role adjuvant treat-
ment after the completion of concurrent chemoirradiation.
The current progress in the treatment of malignant glioma
should fuel interest in further improving the outcome of pa-
tients with brain tumours. Optimizing current agents and
treatment regimens, combination with new cytotoxic and tar-
geted molecules hold promise. The close interaction and inte-
gration of laboratory findings and clinical research will allow
to identifying new treatment targets and are a prerequisite for
individual treatment decisions in the future. The ongoing
EORTC/NCIC randomized trial in low-grade glioma is a good
example.
Optimal management of patients with brain tumours re-
quires an integrated and multidisciplinary approach. Despite
the recent progress and the successful introduction of tem-
ozolomide in clinical practice, further research and develop-
ment of appropriate agents is still needed. Correlative
laboratory studies will help for better understanding of suc-
cesses and failures.Conflict of interest statement
None declared.R E F E R E N C E S1. Walker MD, Alexander E, Hunt WE, et al. Evaluation of BCNU
and/or radiotherapy in the treatment of anaplastic gliomas. A
cooperative clinical trial. J Neurosurg 1978;49:333–43.
2. Walker MD, Green SB, Byar DP, et al. Randomized
comparisons of radiotherapy and nitrosoureas for the
treatment of malignant glioma after surgery. N Engl J Med
1980;303:1323–9.
3. Glioma Meta-Analysis Group. Chemotherapy in adult
high-grade glioma: a systematic review and meta-analysis of
individual patient data from 12 randomised trials. Lancet
2002;359:1011–8.
4. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus
concomitant and adjuvant temozolomide for glioblastoma. N
Engl J Med 2005;352:987–96.
5. Ostermann S, Csajka C, Buclin T, et al. Plasma and
cerebrospinal fluid population pharmacokinetics of
temozolomide in malignant glioma patients. Clin Cancer Res
2004;10:3728–36.
6. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and
pharmacokinetic study of temozolomide (SCH 52365) for
refractory or relapsing malignancies. Br J Cancer
1999;81:1022–30.
E U R O P E A N J O U R N A L O F C A N C E R 4 2 ( 2 0 0 6 ) 5 8 2 –5 8 8 5877. Gerson SL. MGMT: its role in cancer aetiology and cancer
therapeutics. Nature Rev 2004;4:296–307.
8. Liu L, Allay E, Dumenco LL, et al. Rapid repair of
O6-methylguanine–DNA adducts protects transgenic mice
from N-methylnitrosourea-induced thymic lymphomas.
Cancer Res 1994;54:4648–52.
9. Belanich M, Randall T, Pastor MA, et al. Intracellular
localization and intracellular heterogeneity of the
human DNA repair protein 06-methylguanine–DNA
methyltransferase. Cancer Chemother Pharm 1996;37:547–55.
10. Jaeckle KA, Eyre HJ, Townsend JJ, et al. Correlation of tumour
O6 methylguanine–DNA methyltransferase levels with
survival of malignant astrocytoma patients treated with
bis-chloroethylnitrosourea: a southwest oncology group
study. J Clin Oncol 1999;16:3310–5.
11. Belanich M, Pastor M, Randall T, et al. retrospective study of
the correlation between DNA repair protein alkyltransferase
and survival of brain tumour patients treated with
carmustine. Cancer Res 1996;56:783–8.
12. Silber JR, Mueller BA, Eweres TG, et al. Comparison of
O6-methylguanine–DNA methyltransferase activity in brain
tumours and in adjacent normal brain. Cancer Res
1993;53:3416–20.
13. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of
the DNA-repair gene MGMT and the clinical response of
gliomas to alkylating agents. N Engl J Med 2000;343:1350–4.
14. Hegi ME, Diserens A-C, Godard S, et al. Clinical trial
substantiates the predictive value of O-6-methylguanine–DNA
methyltransferase promoter methylation in glioblastoma
patients treated with temozolomide. Clin Cancer Res
2004;15:1871–4.
15. Yung WKA, Prados M, Yaya-Tur R, et al. Multicenter phase II
trial of temozolomide in patients with anaplastic astrocytoma
or anaplastic oligoastrocytoma at first relapse. J Clin Oncol
1999;17:2762–71.
16. Yung WKA, Albright RE, Olson J, et al. A phase II study of
temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. Br J Cancer 2000;83:588–93.
17. Brada M, Hoang-Xuan K, Rampling R, et al. Multicenter phase
II trial of temozolomide in patients with glioblastoma
multiforme at first relapse. Ann Oncol 2000;12:259–66.
18. Brock CS, Newlands ES, Wedge SR. Phase I trial of
Temozolomide using an extende continuous oral schedule.
Cancer Res 1998;58:4363–7.
19. Vera K, Djafari L, Faivre S, et al. Dose-dense regimen of
temozolomide given every other week in patients with
primary central nervous system tumours. Ann Oncol
2004;15:161–71.
20. Spiro TP, Liu L, Majka S, et al. Temozolomide: the effect of
once- and twice-a-day dosing on tumour tissue levels of the
DNA repair protein O(6)-alkylguanine–DNA-alkyltransferase.
Clin Cancer Res 2001;7:2309–17.
21. Tolcher AW, Gerson SL, Denis L, et al. Marked inactivation of
O6-alkylguanine–DNA alkyltransferase activity with
protracted temozolomide schedules. Br J Cancer
2003;88:1004–11.
22. Khan RB, Raizer JJ, Malkin MG, et al. A phase II study of
extended low-dose temozolomide in recurrent malignant
gliomas. Neuro-Oncology 2002;4:39–43.
23. Wick W, Steinbach JP, Ku¨ker WM, et al. One week on/one
week off: a novel active regimen of temozolomide for
recurrent glioblastoma. Neurology 2004;62:2113–5.
24. Su YB, Sohn S, Krown SE, et al. Selective CD4+ lymphopenia
in melanoma patients treated with temozolomide: a toxicity
with therapeutic implications. J Clin Oncol 2004;15:610–6.
25. Mahindra AK, Grossman SA. Pneumocystis carinii pneumonia
in HIV negative patients with primary brain tumours. J
Neuro-Oncol 2003;63:263–70.26. Stupp R, Dietrich P-Y, Osterman-Kraljevic S, et al. Promising
survival for patients with newly diagnosed glioblastoma
multiforme treated with concomitant radiation plus
temozolomide followed by adjuvant temozolomide. J Clin
Oncol 2002;20:1375–82.
27. Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing
and benefit from temozolomide in glioblastoma. N Engl J Med
2005;352:997–1003.
28. Friedman HS, McLendon RE, Kerby T, et al. DNA mismatch
repair and 06-alkylguanine–DNA alkyltransferase and
response to temodal in newly diagnosed malignant glioma. J
Clin Oncol 1998;16:3851–7.
29. Chinot O-L, Barrie M, Frauger E, et al. Phase II study of
temozolomide without radiotherapy in newly diagnosed
glioblastoma multiforme in elderly populations. Cancer
2004;100:2208–14.
30. Glantz M, Chamberlain M, Liu Q, et al. Temozolomide as an
alternative to irradiation for elderly patients with newly
diagnosed malignant gliomas. Cancer 2003;97:2262–6.
31. Roa W, Brasher PMA, Bauman G, et al. Abbreviated course of
radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin
Oncol 2004;22:1583–8.
32. Chang EL, Yi W, Allen PK, et al. Hypofractionated
radiotherapy for elderly or younger low-performance status
glioblastoma patients: outcome and prognostic factors. Int J
Radiat Oncol Biol Phys 2003;56:519–28.
33. Brandes AA, Basso U, Reni M, et al. First-line chemotherapy
with cisplatin plus fractionated temozolomide in recurrent
glioblastoma multiforme: a phase II study of the Gruppo
Italiano Cooperativo di Neuro-Oncologia. J Clin Oncol
2004;22:1598–604.
34. Groves MD, Puduvalli VK, Hess KR, et al. Phase II trial of
temozolomide plus the matrix metalloproteinase inhibitor,
marimastat, in recurrent and progressive glioblastoma
multiforme. J Clin Oncol 2002;20:1383–8.
35. Jaeckle KA, Hess KR, Yung WKA, et al. Phase II evaluation of
temozolomide and 13-cis-retinoic acid for the treatment of
recurrent and progressive malignant glioma: a North
American Brain Tumour Consortium Study. J Clin Oncol
2003;21:2305–11.
36. Fine HA, Wen PY, Maher EA, et al. Phase II trial of thalidomide
and carmustine for patients with recurrent high-grade
gliomas. J Clin Oncol 2003;21:2299–304.
37. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine
plus O6-benzylguanine for patients with nitrosourea-resistant
recurrent or progressive malignant glioma. J Clin Oncol
2002;20:2277–83.
38. Clifford Schold Jr S, Kuhn JG, Chang SM, et al. A phase I trial
of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a
North-American brain tumour consortium study.
Neuro-Oncology 2000;2:34.
39. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of
carmustine plus O6-benzylguanine for patients with recurrent
or progressive malignant glioma. J Clin Oncol 2000;18:3522–8.
40. Quinn JA, Desjardins A, Reardon D, et al. Phase II trial of
temozolomide (temodar) plus O6-benzylguanine in the
treatment of patients with temodar-resistant malignant
glioma. Neuro-Oncology 2004;6:380. (Abstract TA-45).
41. Prados MD, Yung WKA, Fine HA, et al. Phase 2 study of BCNU
and temozolomide for recurrent glioblastoma multiforme:
North American Brain Tumour Consortium study.
Neuro-Oncology 2004;6:33–7.
42. Friedman HS, Petros WP, Friedman A, et al. Irinotecan
therapy in adults with recurrent or progressive malignant
glioma. J Clin Oncol 1999;17:1516–25.
43. Raymond E, Fabbro M, Boige V, et al. Multicentre phase II
study abd pharmacokinetic analysis of irinotecan in
588 E U R O P E A N J O U R N A L O F C A N C E R 4 2 ( 2 0 0 6 ) 5 8 2 –5 8 8chemotherapy-naı¨ve patients with glioblastoma. Ann Oncol
2003;14:603–14.
44. Chamberlain M. Salvage chemotherapy with CPT-11 for
recurrent glioblastoma multiforme. J Neuro-Oncol
2002;56:183–8.
45. Cairncross G, Macdonald D, Ludwin S, et al. Chemotherapy
for anaplastic oligodendroglioma. J Clin Oncol 1994;12:2013–21.
46. van den Bent MJ, Kros JM, Heimans JJ, et al. Response rate and
prognostic factors of recurrent oligodendroglioma treated
with procarbazine, CCNU and vincristine chemotherapy.
Neurology 1998;51:1140–5.
47. Mo¨llemann M, Wolter M, Felsberg J, et al. Frequent promotor
hypermethylation and low expression of the MGMT gene in
oligodendroglial tumours. Int J Cancer 2004;113:379–85.
48. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic
predictors of chemotherapeutic response and survival in
patients with anaplastic oligodendrogliomas. J Natl Cancer Inst
1998;90:1473–9.
49. van den Bent MJ, Looijenga LHJ, Langenberg K, et al.
Chromosomal anomalies in oligodendroglial tumours are
correlated with clinical features. Cancer 2003;97:1276–84.
50. van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II
study of first-line chemotherapy with temozolomide in
recurrent oligodendroglioma: the European Organisation of
Research and Treatment of Cancer Brain Tumour Group study
26971. J Clin Oncol 2003;21:2525–8.
51. van den Bent MJ, Chinot O, Boogerd W, et al. Second-line
chemotherapy with Temozolomide in recurrent
oligodendroglioma after PCV (procarbazine, lomustine and
vincristine) chemotherapy: EORTC Brain Tumour Group phase
II study 26972. Ann Oncol 2003;14:599–602.
52. Triebels V, Taphoorn MJB, Brandes AA, et al. Response to 2nd
line PCV chemotherapy in recurrent oligodendroglioma after
1st line temozolomide. Neurology 2004;63:904–6.
53. Cairncross JG, Seiferheld W, Shaw E, et al. An intergroup
randomized controlled clinical trial (RCT) of chemotherapy
plus radiation (RT) versus RT alone for pure and mixed
anaplastic oligodendrogliomas: initial report of RTOG 94-02.
Proc Am Soc Clin Oncol 2004;23:107. (Abstract # 1500).54. KleinM, Heimans JJ, AaronsonNK, et al. Effect of radiotherapy
and other treatment-related factors onmid-term to long-term
cognitive sequelae in low-grade gliomas: a comparative study.
Lancet 2002;360:1361–8.
55. Brada M, Viviers L, Abson C, et al. Phase II study of primary
temozolomide chemotherapy in patients with WHO grade II
gliomas. Ann Oncol 2003;14:1715–21.
56. Biemond-ter Stege E, Kros JM, de Bruin HG, et al. Treatment of
low-grade oligodendroglial tumours with PCV chemotherapy.
Cancer 2005;103:802–9.
57. Buckner JC, Gesme D, O’Fallon JR, et al. Phase II trial of
procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or
oligoastrocytoma: efficacy and and associations
with chromosomal abnormalities. J Clin Oncol 2003;21:
251–5.
58. Hoang-Xuan K, Capelle L, kujas M, et al. Temozolomide as
initial treatment for adultswith low-gradeoligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p
deletions. J Clin Oncol 2004;22:3133–8.
59. Pace A, Vidiri A, Galie E, et al. Temozolomide
chemotherapy for progressive low-grade glioma: clinical
benefits and radiological response. Ann Oncol 2003;14:
1722–6.
60. Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of
temozolomide in patients with progressive low-grade glioma.
J Clin Oncol 2003;21:646–51.
61. Brandes AA, Tosoni A, Amista P, et al. How effective is BCNU
in recurrent glioblastoma in the modern era? A phase II trial.
Neurology 2004;63:1281–4.
62. Brandes AA, Tosoni A, Basso U, et al. Second-line
chemotherapy with irinotecan plus carmustine in
glioblastoma recurrent or progressive after first-line
temozolomide chemotherapy: a phase II study of the Gruppo
Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol
2004;22:4779–86.
63. Kappele AC, Postma TJ, Taphoorn MJ, et al. PCV
chemotherapy for recurrent glioblastoma multiforme.
Neurology 2001;56:118–20.
